Login to Your Account



Avanir Offering Brings $25M For Neurodex NDA, Pipeline

By Karen Pihl-Carey


Thursday, May 27, 2004
As it nears a new drug application filing for its second product, Avanir Pharmaceuticals Inc. priced a $25 million common stock offering that will allow it to continue development of its pipeline products. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription